A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined with Pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors

  • Voskoboynik, Mark (Primary Chief Investigator (PCI))
  • Brooks, Christine (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date2/02/24 → 1/02/26

Keywords

  • Clinical trial
  • MarkV-01